Neurorehabilitation for Multiple Sclerosis Patients with Emotional Dysfunctions by Yuwen Hung & Pavel Yarmak
January 2016 | Volume 6 | Article 2721
PersPective
published: 25 January 2016
doi: 10.3389/fneur.2015.00272
Frontiers in Neurology | www.frontiersin.org
Edited by: 
Sven Schippling, 
University Hospital Zurich, 
Switzerland
Reviewed by: 
Amy Perrin Ross, 
Loyola University Chicago, USA 
Danielle Rice, 
Loyola University Health System, 
USA
*Correspondence:
Yuwen Hung  
yuwenh@mit.edu.tw, 
yuwen.hung@utoronto.ca
Specialty section: 
This article was submitted to Multiple 
Sclerosis and Neuroimmunology, 
a section of the journal 
Frontiers in Neurology
Received: 21 May 2015
Accepted: 27 December 2015
Published: 25 January 2016
Citation: 
Hung Y and Yarmak P (2016) 
Neurorehabilitation for Multiple 
Sclerosis Patients with Emotional 
Dysfunctions. 
Front. Neurol. 6:272. 
doi: 10.3389/fneur.2015.00272
Neurorehabilitation for Multiple 
sclerosis Patients with emotional 
Dysfunctions
Yuwen Hung1,2* and Pavel Yarmak2,3
1 Martinos Imaging Center, McGovern Institute for Brain Research, Harvard-Massachusetts Institute of Technology, 
Cambridge, MA, USA, 2Neurosurgery, Neuroscience Research Center, St. Michael’s Hospital, Toronto, ON, Canada, 
3 Psychology and Neuroscience, University of Toronto, Toronto, ON, Canada
Depression frequently develops in multiple sclerosis (MS) patients, exacerbating the 
manifestations of the disease and making its management challenging. To date, no 
consensus has been reached regarding effective treatments for these sufferers due to 
limited understanding regarding the underlying mechanisms responsible for emotional 
disorders that are highly comorbid with this disease. There is an urgent need to rethink 
current treatment options for these patients. This article aims to optimize the treatment 
outcomes and improve the quality of life for MS patients. Based on an in-depth and 
critical review of the current literature, we provide a neurorehabilitative framework that 
explains possible regulatory mechanisms underlying the emotional symptoms highly 
developed in MS. This article offers practical knowledge and therapeutic strategies to 
optimize the treatment options in the current care system for MS, as well as for other 
disabling diseases.
Keywords: multiple sclerosis, emotional disorders, neuropsychiatry, psychotherapy, neurocognitive rehabilitation
Approximately half of all patients with multiple sclerosis (MS) experience clinically significant 
depression at least once in their lifetimes and even more exhibit emotional symptoms. The depres-
sive disorders observed in MS exacerbate the manifestations of the disease and make its manage-
ment challenging (1). Yet, the majority of MS patients with depressive symptoms receive neither 
antidepressant medication nor psychotherapy. The side effect profile of conventional antidepressant 
treatments can complicate MS management, compromising treatment efficacy and compliance (2). 
No consensus to date has been reached regarding effective treatment options for these sufferers, 
due to limited understanding regarding the underlying mechanisms that may be responsible for 
the emotional disorders that are highly comorbid with MS. There is therefore an urgent need for 
clinicians and neuroscientists to rethink current treatment options for these patients and improve 
the quality of their care. Here, we provide a neurorehabilitative framework that explains possible 
regulatory mechanisms underlying the emotional symptoms frequently developed in MS and sug-
gest practical strategies to optimize its treatment outcomes.
Patients with MS, a heterogeneous central nervous system disease causing focal brain lesions 
and diffuse demyelination, suffer from pronounced physical and cognitive disabilities (3). Though 
retaining their intellectual abilities, MS patients exhibit various cognitive deficits involving both 
verbal and non-verbal memory, attention and speed of processing, as well as executive function-
ing. The progression of MS introduces a chronic stress in patients, associated with impaired 
neurocognitive functions and diminished brain resources (cognitive reserve), which involve 
pathology of not only the cortex but also deep brain structures, including the limbic system. 
AB
C
D
E
FiGUre 1 | A neurorehabilitative approach for optimizing the Ms 
treatment. (A,B) MS introduces a chronic stress, associated with impaired 
neurocognitive functions and reduced brain resources, which involves 
cortical–subcortical communications – particularly the prefrontal-amygdala 
connections, areas important for emotional regulation. (B,c) MS patients 
experience negative attentional bias and maladaptive cognitive appraisal 
toward daily life events because of abnormal processing and insufficient 
cognitive resources in the emotionally dysregulated brain, which create a 
susceptibility to the development of emotional dysfunctions. Given the 
complex relationship between the neurocognitive dysfunctions and 
depressive susceptibility in MS, it is advisable to combine psychotherapy (D) 
with neurocognitive rehabilitation (e) in future MS treatment options.
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In particular, impaired brain connectivity in MS patients has 
been observed between the prefrontal lobe and the amygdale 
(4)  –  brain circuits important for the regulation of emotions 
(Figures  1A,B) (5). Deficits in executive functions also 
contribute to problems of impulsivity and lack of emotional 
control. Abnormal emotional processing takes place in the 
dysregulated brain with limited neurocognitive resources, and 
the MS patients experience negative attentional bias and use 
maladaptive cognitive appraisal toward daily life events. These 
cognitive deficiencies create a susceptibility to the develop-
ment of emotional symptoms and disorders such as depression 
(Figures  1B,C). Neuroimaging evidence suggests that the 
depressive symptoms in MS are related to the total extent of 
brain lesions and the degree of impaired cortical-subcortical 
connections (6).
This framework lays an important foundation to explain how 
neuropsychotherapy can be an alternative to antidepressants 
for MS patients with active depressive symptom. Specifically, 
based on the complex interplay between the neurocognitive 
dysfunctions and depressive susceptibility in MS, it is advis-
able to consider combining psychotherapy with neurocognitive 
rehabilitation in current MS treatment options to optimize 
treatment outcomes. It has been found that emotional distress 
in the MS patients is associated with poor coping and acceptance 
rather than disease duration or severity (7). Stress management 
and better coping strategies have been shown to be related to 
increased psychological well-being in people with MS (8). 
Emotional reappraisal strategies, regardless of the severity of 
the disease, can further improve the quality of life with MS (9). 
Cognitive-behavioral therapy (CBT) has recently been found to 
be an effective means of treating depressed MS patients (10, 11). 
This psychotherapy enables the top-down, prefrontal-related 
regulatory processes to mitigate negative emotional reactions 
(12), with an efficacy similar to antidepressant treatments. CBT 
corrects the MS patients’ negative attention and perception 
toward daily challenges as well as adjusting their maladaptive 
ways of thinking – negative cognitive appraisal – which eventu-
ally produce a depressed mood (13). This intervention can help 
patients with MS learn to cope with existing and continuing 
cognitive impairments by adopting a more realistic cognitive 
frame to lower their stress levels when negative situations cannot 
be avoided (Figure 1D).
Lastly, neurocognitive rehabilitation treatment can be effective 
in ameliorating patients’ cognitive deficiencies (14), both objec-
tively and subjectively, while relieving the depressive symptoms. 
The rehabilitative intervention aims to retrain the impaired 
cognitive functions and allow the brain to maximize cognitive 
capacity (reserve) or to utilize a compensatory network (neural 
plasticity). Depending on the cognitive symptoms, the rehabilita-
tive exercises target functions including attention (e.g., focusing), 
memory, and working memory, as well as executive functions 
and learning strategies (e.g., goal attainment). Future cognitive 
training may benefit from considering higher-level, prefrontal-
related executive processing to strengthen the cognitive controls 
and facilitate regulative processes for affective functioning (e.g., 
impulse control including inhibition and attention training 
involving attention shifting and disengaging) (Figure  1E). The 
cognitive retraining for MS patients may also facilitate the effects 
of CBT through positive feedback that increases the patients’ 
self-efficacy (self autonomy). Currently, cognitive rehabilitative 
exercises have not been well established for patients with MS, 
relative to other neurological diseases (e.g., stroke), possibly due 
to the highly varied neuropsychological profiles among individu-
als with MS.
Given the emotionally afflicting nature of MS and the high risk 
of patients developing affective dysfunctions, it is also important 
to consider early, preventative intervention, before a definite 
diagnosis of depression is made. Such intervention can include 
adding screening tests for initial signs of depression and identify-
ing at-risk MS patients (e.g., those with emotional dysregulation 
symptoms). These directions would not only facilitate treatment 
outcomes for the MS patients, but would also potentially lower 
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the substantial incidence of depression in MS. For future research 
and treatment planning, a multimodal approach may be the 
key to optimizing treatment outcomes for many people suf-
fering from MS and related diseases (15).
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